Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Novo Nordisk is opening a new front in its fight ... The biotech’s road map includes IND-enabling studies and phase 1 trials in 2026 and 2027. Novo will now take responsibility for the studies.

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments ... “Our goal here was to literally map the landscape by association or create an atlas ...

Vietnam’s pharmaceutical market is expected to have a year of optimism after experiencing a multicoloured gamut in 2024.

The mining company that owns the licence to Greenland's Kvanefjeld deposit is hopeful that a new government will repeal a ban ...

"Trump might forget about Greenland. But also, he might not. Nobody knows. He operates on whims," @anneapplebaum writes.

A team of investigators from Dana-Farber Cancer Institute, The Broad Institute of MIT and Harvard, Google, and Columbia University have created an artificial intelligence model that can predict which ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...